Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bladder cancer

Advancing NMIBC treatment beyond current BCG formulations

Nature Reviews Urology volume 14, pages 12–13 (2017)Cite this article

Subjects

Multiple BCG strains are used for intravesical instillation treatment of non-muscle-invasive bladder cancer but no large randomized studies comparing these strains are available. To enable creation of new BCG-related agents that overcome the instabilities of the current formulations, molecular examination of BCG's mechanisms of action is required.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology, bladder cancer (2016 version 2). NCCN https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (2016).

  2. Hinotsu, S. et al. Sustained prophylactic effect of intravesical bacille Calmette–Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 67, 545–549 (2006).

    Article  Google Scholar 

  3. Witjes, J. A. et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol. Oncol. 34, 484.e19–484.e25 (2016).

    Article  Google Scholar 

  4. Hinotsu, S., Kamatani, N., Ratliff, T. L. & Akaza, H. A systematic review and meta-analysis on the safety and efficacy of different strains of Mycobacterium bovis bacillus Calmette–Guérin for non-muscle invasive bladder cancer in Japan and US. Eur. J. Oncol. Pharm. 8, 8–18 (2014).

    Google Scholar 

  5. Gan, C., Mostafid, H., Khan, M. S. & Lewis, D. J. BCG immunotherapy for bladder cancer — the effects of substrain differences. Nat. Rev. Urol. 10, 580–588 (2013).

    Article  CAS  Google Scholar 

  6. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology, bladder cancer (Asia consensus statement 2016 version 1). NCCN https://www.nccn.org/professionals/physician_gls/PDF/bladder-asia.pdf (2016).

  7. Morales, A. & Cohen, Z. Mycobacterium phlei cell wall–nucleic acid complex in the treatment of non-muscle invasive bladder cancer unresponsive to bacillus Calmette–Guérin. Expert Opin. Biol. Ther. 16, 273–283 (2016).

    Article  CAS  Google Scholar 

  8. Miyazaki, J. et al. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette–Guérin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands. BJU Int. 108, 1520–1526 (2011).

    Article  CAS  Google Scholar 

  9. Massard, C. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119–3125 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hideyuki Akaza is at the Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies/Graduate School of Interdisciplinary Information Studies, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo 153–8904, Japan.,

    Hideyuki Akaza

Authors
  1. Hideyuki Akaza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideyuki Akaza.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akaza, H. Advancing NMIBC treatment beyond current BCG formulations. Nat Rev Urol 14, 12–13 (2017). https://doi.org/10.1038/nrurol.2016.248

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.248

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing